Peter David Suzdak Insider Trading $RNN Ocuphire Pharma, Inc.
FREE EMAIL WATCHDOG
Get free email notifications about insider trading for Peter David Suzdak.
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insider Transactions | Monthly Overview
Get the latest insider transactions of Peter David Suzdak. Peter David Suzdak is Chief Executive Officer in REXAHN PHARMACEUTICALS, INC. ($RNN) and Director in AEOLUS PHARMACEUTICALS, INC. ($INCR.OB).
Peter David Suzdak in Ocuphire Pharma, Inc.
Industry: PHARMACEUTICAL PREPARATIONS [2834]
Position of Peter David Suzdak: Chief Executive Officer
Holdings: 22,250 shares
Current Value: $4,005
Latest Transaction: Mar 02 2018
$RNN Market Capitalization: $41.78M
$RNN Previous Close: $0.18
Last 4 weeks trend: HOLD
Last 3 months trend: HOLD
Latest Insider Trading Transactions of Peter David Suzdak in Ocuphire Pharma, Inc.
| 1 Week | 2 Weeks | 1 Month | 3 Months | 6 Months | 1 Year | 2 Years | |
|---|---|---|---|---|---|---|---|
| No. of Purchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Value of Purchases ($) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| No. of Sales | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Value of Sales ($) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Page: 1
| Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 02 2018 | RNN | REXAHN PHARMACEUTI ... | Suzdak Peter David | Chief Executive Off ... | Option Exercise | M | 0.00 | 6,250 | 0 | 18,750 | |
| Mar 02 2018 | RNN | REXAHN PHARMACEUTI ... | Suzdak Peter David | Chief Executive Off ... | Buy | M | 0.00 | 6,250 | 0 | 22,250 | 16 K to 22.3 K (+39.06 %) |
| Jan 30 2018 | RNN | REXAHN PHARMACEUTI ... | Suzdak Peter David | Chief Executive Off ... | Option Exercise | A | 2.29 | 112,271 | 257,101 | 112,271 | |
| Aug 16 2017 | RNN | REXAHN PHARMACEUTI ... | Suzdak Peter David | Chief Executive Off ... | Grant | A | 1.99 | 10,000 | 19,872 | 16,000 | 6 K to 16 K (+166.67 %) |
| Jan 24 2017 | RNN | REXAHN PHARMACEUTI ... | Suzdak Peter David | Chief Executive Off ... | Option Exercise | A | 0.00 | 250,000 | 0 | 250,000 | |
| Jan 24 2017 | RNN | REXAHN PHARMACEUTI ... | Suzdak Peter David | Chief Executive Off ... | Option Exercise | A | 0.18 | 1,175,000 | 216,200 | 1,175,000 | |
| Mar 21 2016 | RNN | REXAHN PHARMACEUTI ... | Suzdak Peter David | Chief Executive Off ... | Grant | A | 0.32 | 60,000 | 19,386 | 60,000 | 0 to 60 K |
| Feb 01 2016 | RNN | REXAHN PHARMACEUTI ... | Suzdak Peter David | Chief Executive Off ... | Option Exercise | A | 0.35 | 1,000,000 | 350,000 | 1,000,000 | |
| Feb 01 2016 | RNN | REXAHN PHARMACEUTI ... | Suzdak Peter David | Chief Executive Off ... | Option Exercise | A | 0.35 | 411,689 | 144,091 | 411,689 |
Page: 1